Damage Control Resuscitation (CPG ID:18)
This CPG provides evidence–based guidance to minimize variation in resuscitation practices and improve the care of massively hemorrhaging, severely injured casualties.

Contributors

COL Andrew P Cap, MC, USA
COL Jennifer Gurney, MC, USA
Philip C. Spinella, MD, FCCM
CDR Geir Strandenes, MC, Norwegian Special Forces
COL (ret) Martin Schreiber, MC, USAR
COL (ret) John Holcomb, MC, USAR
LTC Jason B. Corley, MC, USA
Col (ret) Donald Jenkins, USAF, MC
COL (ret) Brian Eastridge, MC, USAR
LCDR Russell Wier, MC, USN
Lt Col Brian Gavitt, USAF, MC
RDML Darin K Via, MC, USN
LTC Matthew A Borgman, MC, USA
Maj Andrew N Beckett, MC, Canadian Forces
Col Tom Woolley, FRCA, RAMC
CAPT (ret) Joseph Rappold, MC, USN
LTC Kevin Ward, MC, USAR
Col Michael Reade, MC, Australian Defense Forces
COL Sylvain Ausset, MC, French Army
SGT Ricky M Ditzel Jr, MC, USA
Col Stacy Shackelford, USAF, MC
CDR Jacob Glaser, MC, USN

First Publication Date: 18 Dec 2004  Publication Date: 12 Jul 2019  Publication Supersedes: 03 Feb 2017

TABLE OF CONTENTS

Executive Summary and Updates ................................................................. 3
Summary of Updates: .............................................................................. 3
Background ............................................................................................... 3
Blood Products for DCR ........................................................................... 5
Whole Blood ............................................................................................. 5
Red Blood Cells ........................................................................................ 6
Plasma ........................................................................................................ 6
Platelets ..................................................................................................... 7
Hemostatic Adjuncts for DCR ................................................................. 7
Mechanical Hemorrhage Control ......................................................... 7
Pharmacologic Adjuncts ......................................................................... 8
Management Principles for DCR ......................................................... 9
Recognition of Patients Requiring DCR ............................................. 9
Point of Injury, En-Route, and Remote DCR ........................................ 10
Optimization of Fluids ......................................................................... 10
Adjunctive Therapies in PFC ............................................................... 11
Damage Control Resuscitation

Compressive/Hemostatic Dressings and Devices ................................................................. 11
Prevention of Acidosis and Hypothermia ................................................................. 11
Expeditious Delivery to Definitive Surgical Control .................................................. 11
DCR at Medical Treatment Facility ........................................................................... 11
Optimization of Fluids .......................................................................................... 12
Blood Product Transfusion .................................................................................. 12
Adjunctive Therapies at Medical Treatment Facilities ........................................ 12
Hypotensive Resuscitation .................................................................................. 12
Compressive/Hemostatic Dressings and Devices ................................................ 12
Prevention or Correction of Hyperfibrinolysis ........................................................ 13
Prevention of Acidosis and Hypothermia .......................................................... 13
Expeditious Delivery to Definitive Surgical Control .............................................. 13
Conclusion ........................................................................................................... 13
Performance Improvement (PI) Monitoring .......................................................... 13
Population of Interest .......................................................................................... 13
Intent (Expected Outcomes) ................................................................................ 14
Performance/Adherence Metrics ........................................................................ 14
Data Sources ......................................................................................................... 14
System Reporting & Frequency ........................................................................... 15
Responsibilities ..................................................................................................... 15
References ........................................................................................................... 15
Appendix A: Example of a Massive Transfusion Procedure at USCENTCOM Level III Facility ........................................... 21
Appendix B: Pediatric Considerations ...................................................................... 22
Appendix C: Additional Information Regarding Off-label Uses in CPGs ................. 24
EXECUTIVE SUMMARY AND UPDATES

Hemorrhage is the leading cause of preventable death on the battlefield. Of the 4,596 combat deaths reported in COL Brian Eastridge’s 2012 review Death on the Battlefield, 976 casualties died with injuries that an expert panel classified as potentially survivable, and the vast majority of these deaths—just over 90%—were secondary to uncontrolled hemorrhage. Subsequent interventions focusing on point of injury hemorrhage control and prehospital Tactical Combat Casualty Care were predictably successful, and particularly when paired with rapid evacuation and prehospital blood resuscitation. In fact, data published in studies by Col Stacy Shackelford et al. showed that blood given in the prehospital setting as soon as possible after injury improved both 24 hour and 30 day survival. In short, in the setting of active hemorrhage, the combination of point-of-injury hemorrhage control (per Tactical Combat Casualty Care guidelines), rapid evacuation, and pre-hospital blood resuscitation saves lives.

SUMMARY OF UPDATES:

- Greater emphasis on the use of Low Titer O Whole Blood (LTOWB) as the optimal strategy to deliver a balanced and maximally hemostatic resuscitation, with platelet functionality, safely.
- Risk factors for massive transfusion (MT), International Normalized Ratio (INR) threshold updated to > 1.5.
- Earlier calcium use recommended. One gram of calcium (30 ml of 10% calcium gluconate or 10 ml of 10% calcium chloride) IV/IO should be given to patients in hemorrhagic shock during or immediately after transfusion of the first unit of blood product and with ongoing resuscitation after every 4 units of blood products. Ideally, ionized calcium should be monitored and calcium should be given for ionized calcium less than 1.2mmol/L.
- Blood pressure goals for DCR have been adjusted to a target systolic blood pressure (SBP) goal of 100 mmHg (110mmHg for traumatic brain injury (TBI)).
- Resuscitative Endovascular Balloon Occlusion of the Aorta (REBOA) updated as a fielded option for the control of non-compressible torso hemorrhage. REBOA continues to be recommended for designated resuscitation teams and NOT intended to be used by the combat medic or corpsman.
- The use of hydroxyethyl starch (Hextend, Hespan) as a resuscitation fluid is NO LONGER RECOMMENDED and has been removed from the guideline.
- The use of recombinant human activated factor VII (rhFVIIa) is no longer recommended.

BACKGROUND

Damage Control Resuscitation (DCR) is generally accepted as a complementary strategy usually paired with Damage Control Surgery (DCS), which focuses surgical interventions to those which address life-threatening injuries and delays all other surgical care until metabolic and physiologic derangements have been treated. Recognizing that this approach saved lives, DCR was developed to work synergistically with DCS and prioritize non-surgical interventions which may reduce morbidity and mortality from trauma and hemorrhage. The major principle of DCR is to restore homeostasis, prevent or mitigate the development of tissue hypoxia, oxygen debt and burden of shock, as well as coagulopathy. This amounts to preventing ‘blood failure,’ specifically with a goal of restoring blood functionality (improving oxygen delivery and tissue perfusion, reducing acidosis, preventing fibrinolysis,
Damage Control Resuscitation

reducing coagulopathy, protecting the endothelium, and reducing platelet dysfunction). This is best accomplished through aggressive hemorrhage control and a blood product-based resuscitation, which restores tissue oxygenation, avoids platelet and coagulation factor dilution, and also replaces lost hemostatic potential. DCR is most effective when resuscitation replaces lost blood with whole blood, whether ideally transfused as units of whole blood (WB), or blood product components transfused in a ratio approximating whole blood (i.e. 1:1:1 ratio of FFP:Plt:RBC). Additional goals of DCR are avoidance or limiting of the use of crystalloids to avoid dilutional coagulopathy, selective use of hypotensive resuscitation (SBP of 100 or SBP of 110, if TBI suspected until surgical control is achieved, correction of coagulopathy and acidosis, maintenance of normothermia, empiric administration of Tranexamic Acid in appropriate patient populations, and expeditious evacuation to damage control and definitive surgical capabilities.

Advanced Trauma Life Support (ATLS) guidelines historically advocated a linear resuscitation strategy beginning with an emphasis on crystalloid infusion, particularly during the pre-hospital phase, followed by the addition of red blood cells (RBCs), and finally plasma. Platelets were delayed until a low platelet count was documented and reserved either for severe thrombocytopenia or thrombocytopenia in the presence of active hemorrhage. As documented in retrospective reports from the civilian trauma literature, this approach resulted in excessive crystalloid use and is associated with a risk of dilutional coagulopathy, abdominal compartment syndrome, multiple organ failure, and death. Although selection bias may have contributed to these findings, it should be noted that the ATLS 10th edition identifies that resuscitation with greater than 1.5L of crystalloid is associated with increased mortality, and suggests limiting crystalloid use to no more than one liter during the initial resuscitation. Instead, current ATLS recommendations for bleeding patients are for early administration of blood products, including plasma and platelets, while focusing on rapidly achieving hemorrhage control.

During the conflicts in Iraq and Afghanistan between 2003 and 2012, 14% of patients admitted to Role 3 military treatment facilities (e.g., combat support hospitals) received a transfusion of at least one blood product. Of these, 35% received MT. (MT is defined as ≥ 10 units of RBCs and/or WB in 24 hours. The proportion of transfused patients receiving MT reached approximately 50% by 2011 in parallel with increasing injury severity scores, use of blood resuscitation, and decreased use of crystalloid and colloid use. During this period mortality fell as military clinicians became experts in the treatment of very severe multisystem trauma accompanied by massive hemorrhage. Civilian ATLS-based practice gave way to a hemostatic resuscitation approach designed to mimic WB functionality.

There is now strong retrospective evidence in both civilian and military trauma populations that patients requiring MT benefit from a higher ratio of plasma and platelets to red cells (e.g., 1 unit plasma: 1 unit platelets: 1 unit RBCs). MT at a 1:1:1 ratio is associated with improved survival. Recently, prospective randomized data from the Pragmatic Randomized Optimal Platelet and Plasma Ratios (PROPPR) trial revealed that mortality at 3 hours after injury due to exsanguination was lower in patients resuscitated with a 1:1:1 ratio compared to 1:1:2. These were important findings given that the differences between resuscitation strategies were small—and probably best characterized by an early vs. late platelet approach. There was no difference in overall mortality at 24 hours or 30 days, likely due to the confounding effect of head injury. Balanced resuscitation was not associated with increased complication rates.

Although physicians continue to debate the lessons of the PROPPR trial and the relative benefits of specific blood component ratios, the practice of giving large amounts of crystalloid or RBCs alone during the initial resuscitation is no longer standard practice. As stated above, in combat casualties with
bleeding, EARLY blood product resuscitation (ideally within 36 minutes of injury) provides the lowest early and late mortality rates.\textsuperscript{2} Available data on balanced resuscitation comes from component based resuscitation. We know that any blood product combination represents an advantage over salt based crystalloids for the bleeding casualty. However, LTOWB represents the best way to deliver a functional resuscitation early, clinically as well as logistically.

**BLOOD PRODUCTS FOR DCR**

### WHOLE BLOOD

Whole blood delivers all the components of blood in the same ratio in which they were lost; WB is independently associated with improved survival.\textsuperscript{21-23} In deployed environments, the logistical challenges of maintaining a supply of blood components has led to the use of WB collected onsite from “walking blood banks,” especially to provide platelets for hemostatic resuscitation. Depending where the blood products have been collected, some of the whole blood products in the deployed setting (platelets or WB) are not prospectively tested for Transfusion-Transmitted Diseases (TTDs). Rapid TTD test kit use is encouraged to screen for HIV, Hepatitis B and C, and malaria or other diseases for which kits are available. Recipients of these blood products must be tested at 3, 6 and 12 months post-transfusion to monitor for disease transmission.

Type-Specific Whole Blood (TSWB), often referred to as Fresh Whole Blood (FWB), is collected from donors in the deployed setting and must be an ABO match with the recipient. The availability of TSWB may be limited due the constrained pool of donors who must be tested for TTDs and blood group compatibility with recipients. In addition, the chaotic conditions of mass casualty scenarios complicate the matching of blood types between donors and recipients, increasing the risk of clerical errors causing hemolytic transfusion reactions.

In order to improve the availability and safety of WB, low anti-A and anti-B titer (<256 by tube method, though the definition of ‘low titer’ can vary by medical agency or facility) group O blood has been identified as a practical, effective universal blood product for resuscitation of exsanguinating hemorrhage.\textsuperscript{24,25} Like all blood donors, “O low titer” donors should be tested for TTDs and undergo confirmatory typing and an antibody screen (type and screen) in addition to testing for anti-A and anti-B antibodies. LTOWB can be collected from pre-screened walking blood banks in the deployed setting or collected in Armed Services Blood Program donor centers and stored refrigerated for 21 days in CPD or 35 days in CPDA-1.\textsuperscript{26} It is important to note that LTOWB has been used safely in the military setting since WW1, with hundreds of thousands of units transfused and only one recorded hemolytic reaction, due to a clerical error.\textsuperscript{27}

In 2014 the U.S. Army Rangers developed and instituted the Ranger O Low titer blood (ROLO) program. Low Titer Rangers were identified as a screened donor pool serving as an immediate WBB capability (approximately 2/3 of the group O Ranger population is naturally low titer, generally accepted as having anti-A and anti-B levels less than 1:256 concentration). Every Ranger is trained in how to set up and administer a Fresh Whole Blood buddy transfusion. This program represents a success story of leadership and since 2015 every Ranger task force has deployed with a functional ROLO program. This model is currently being broadened to other prehospital communities.

Available data suggest that Cold-Store WB (CWB) will provide robust platelet hemostatic function during the first 2 weeks of storage. When using anticoagulants and preservatives such as CPD and CPD-
A, function is moderately reduced during the remaining shelf life (21 days for Citrate Phosphate Dextrose (CPD) WB and 35 days for Citrate Phosphate Dextrose Adenine (CPDA-1) WB), but it should be noted that some platelet function remains and that WB plasma hemostatic function is comparable to that of liquid plasma. Throughout its shelf life, CWB remains a relatively hemostatic product compared to RBCs and plasma alone. Patients receiving MT with CWB stored for more than 2 weeks may require additional support with platelet transfusions or FWB (consider a ratio of 3:1 of CWB: FWB as available). Similarly, CWB that has been leukoreduced with a filter that does not spare platelets and that contains fewer or effectively no platelets requires supplementation with platelet or FWB transfusion.

Cold-stored LTOWB and TSWB have been used successfully and safely to treat trauma and other causes of massive hemorrhage, such as obstetric emergencies and bleeding in cardiac surgery, in leading U.S. civilian hospitals.

WB is standard practice for resuscitation of combat casualties. For guidance regarding use of FWB, see the Joint Trauma System (JTS) CPG entitled Fresh Whole Blood Transfusion.

RED BLOOD CELLS

RBC units may be stored for up to 42 days under refrigeration when stored in additive solution (e.g., AS-5) or 35 days if stored in CPDA1. In addition, “frozen” RBCs (stored frozen with glycerol cryoprotectant for up to 10 years at <-65°C, then thawed and rinsed in an automated process prior to transfusion) are used interchangeably and successfully with standard RBC units when needed, although these units require at least an hour and a half and specialized equipment to prepare. Transfusion of thawed RBC units without removal of glycerol is absolutely contraindicated and is lethal to the recipient. Thawed and deglycerolized RBCs can be stored for 14 days with refrigeration. For guidance regarding use of fRBCs see the JTS CPG entitled Frozen and Deglycerolized Red Blood Cells.

PLASMA

Plasma can be stored frozen and then thawed on-demand (FFP), or pre-thawed and stored refrigerated for up to 5 days (so-called “thawed plasma”). The delay in treatment imposed by slow thawing of FFP (up to 30 minutes or more) has necessitated the widespread maintenance of thawed plasma inventories for immediate, emergency use. This typically results in significant waste due to the 5-day post-thaw shelf life. Plasma can also be supplied as “liquid” (never frozen) plasma and stored for 26 days in CPD anticoagulant solution, or 40 days in CPDA-1. Available data suggest that “thawed” and “liquid” plasma may be functionally interchangeable in most trauma patients. Note that no randomized trials have compared these products and the data regarding the hemostatic capacity of liquid plasma stored beyond 28 days are very limited. Although group AB plasma is classically considered the universal donor, it is now widely recognized that A plasma can, in fact, be considered universal since group A individuals do not generally make high titer anti-B antibodies and B red cells express the B antigen at low density, thus making them much less susceptible to hemolysis than A red cells.

Freeze-Dried Plasma (FDP) was used by U.S. Forces during World War II and has been in use by the French military since the 1940s. French military FDP is available to U.S. Special Operations Forces under an Emergency Use Authorization from the Food and Drug Administration (FDA). FDP is considered functionally interchangeable with other plasma products for trauma resuscitation. FDP or Spray-Dried Plasma (SDP) may become more broadly available to U.S. Forces in the near future.
PLATELETS

In contrast to red cells and plasma, platelets collected in theater by apheresis traditionally have been stored at room temperature (20-24°C), under constant agitation, for a maximum of 5 days with an extension to 7 days total if shipped to another facility. These storage conditions are optimized to extend in vivo platelet circulation, but not hemostatic function, safety, or availability. Platelets are vital for hemostasis and their early use in a balanced transfusion strategy is associated with increased survival in trauma. Platelets stored under refrigeration (1-6°C), or “Cold-Stored Platelets” (CSP), maintained without agitation for up to 3 days in plasma, have long been approved by the FDA for treatment of bleeding patients. Refrigerated storage better preserves platelet hemostatic function and clearly reduces the risk of bacterial growth, the major hazard of transfusing room temperature-stored platelets. CSP have been proven effective in clinical trials and used successfully in combat trauma patients in the U.S. Central Command area of operations. Cold-stored platelets in platelet additive solution (CSP-PAS) or plasma retain function for at least 15 days and are compatible with blood warmers and rapid infusers. CSP can be collected in theater and used interchangeably with other platelet products.

Fibrinogen concentrate has not been studied adequately in trauma patients either, but several factors suggest that it may be helpful. These include: 1) fibrinogen is the fundamental substrate of clot formation; 2) fibrinogen is rapidly consumed in trauma; and 3) cryoprecipitate, a less purified source of fibrinogen, has been shown to be an essential component of MT protocols for mitigating the dilutional coagulopathy caused by red cell additive solution and anticoagulant.

Prothrombin Complex Concentrates (PCCs) are only indicated for patients requiring urgent warfarin reversal and have not been adequately studied in a broad trauma population. PCCs could be considered if: 1) the patient is anticoagulated; or 2) there is clear evidence of delayed initiation of clot formation refractory to platelets, fibrinogen or cryoprecipitate and TXA (e.g., prolonged thrombelastography rapid time [TEG-R] or rotational thromboelastometry clotting time [ROTEM CT]). PCCs should not be routinely used in trauma outside the context of a clinical trial as they may cause harm due to excessive thrombogenicity.

HEMOSTATIC ADJUNCTS FOR DCR

MECHANICAL HEMORRHAGE CONTROL

In addition to blood replacement, DCR strategies also focus on limiting blood loss with hemorrhage control devices and adjunctive pharmaceutical therapies. Availability and usefulness of interventions are determined by the type of injury and location of bleeding. Effective tourniquets (e.g., Combat Application Tourniquet, Special Operations Forces Tactical Tourniquet) have been developed for extremity injury and may be responsible for saving more wounded service members in Iraq and Afghanistan than any other single medical intervention. Junctional (axillary, neck, and groin) hemorrhage, previously a nearly intractable problem, can now be treated with approved junctional tourniquets (e.g., Combat Ready Clamp, SAM® Junctional Tourniquet, Junctional Emergency Treatment Tool) and the XSTAT™ device, which injects absorbent sponges into deep wounds to tamponade bleeding. Superficial wounds are amenable to novel and effective hemostatic dressings (e.g., Combat Gauze or Celox/Celox Rapid gauze).
Truncal internal hemorrhage is non-compressible and is the subject of intensive research. Resuscitative Endovascular Occlusion of the Aorta (REBOA) has emerged as a technique for truncal hemorrhage control. The newest device available does not require fluoroscopic guidance and has become widely available; in expert hands on teams with appropriate training, REBOA may improve survival from non-compressible truncal hemorrhage. There is no 24-hour outcome data on the use of REBOA in the combat environment. Teams that use this technique should be submitting clinical data to the JTS in order to better understand this capability and how it effects outcomes from hemorrhage. The ideal application of REBOA in the combat environment is evolving, but the technique, when used appropriately, has the potential to significantly improve outcomes from non-compressible truncal hemorrhage. Currently, REBOA use is supported for austere surgical teams, and teams that have an immediate surgical capability are using REBOA. See the JTS REBOA for Hemorrhagic Shock CPG.

PHARMACOLOGIC ADJUNCTS

Hemostatic pharmaceutical adjuncts to limit blood loss are another subject of considerable investigation.

Tranexamic acid (TXA) is the only therapy in this class that has been found to reduce mortality in a large Randomized Controlled Trial (RCT). Strong evidence demonstrates a significant improvement in survival following the early use of TXA, but only when given within 3 hours of injury. Significant trauma--in particular, penetrating trauma with hemorrhage--has been associated with coagulopathy, in part secondary to the activation of fibrinolysis. Such hyperfibrinolysis occurs in the most severely injured patients (approximately 4% of trauma patients in major civilian U.S. trauma centers) and portends poor outcomes. Anti-fibrinolytic agents, including TXA, have been used to decrease bleeding and to reduce the need for blood transfusions in coronary artery bypass grafting, orthotopic liver transplantation, hip and knee arthroplasty, obstetrics, and other surgical settings. The safety and efficacy of using TXA to treat trauma patients was evaluated in a large randomized, placebo-controlled clinical trial The Clinical Randomization of an Antifibrinolytic in Significant Hemorrhage (CRASH-2). In this trial, 20,211 adult trauma patients in 274 hospitals in 40 countries with, or at risk of, significant bleeding (HR>110, SBP<90, clinical judgment) were randomized to either TXA or placebo. The authors reported that TXA use resulted in a statistically significant reduction in the relative risk of all-cause mortality of 9% (14.5% vs. 16.0%, RR 0.91, CI 0.85-0.97; p = 0.0035). It was in this group of most severely injured patients that use of TXA was associated with the greatest reduction in risk of death.

A registry-based study of combat-injured troops receiving blood in Afghanistan (January 2009 - December 2010) demonstrated a decreased mortality with TXA use in this population. The TXA group was more severely injured (ISS: 25.2±16.6 vs. 22.5±18.5; p<0.001), required more blood (11.8±12.1 vs. 9.8±13.1 pRBC units; p<0.001), had a lower Glasgow Coma Score (7.3±5.5 vs. 10.5±5.5; p<0.001) and initial systolic blood pressure (112±29.1 vs. 122.5±30.3 mmHg), but also had a lower unadjusted mortality than the no-TXA group (17.4% vs. 23.9%; p=0.028). In the massive transfusion cohort (N=321; 24 hour transfusion: 21.9±14.7 pRBC; 19.1±13.3 FFP and 3.5±3.2 apheresis platelet units), mortality was also lower in the TXA group compared to the no-TXA group (14.4% vs. 28.1%; p=0.004). In a multivariate regression model, TXA use in the massive transfusion cohort was independently associated with survival (odds ratio: 7.28; 95% confidence interval: 3.02-17.32). A subsequent larger retrospective analysis of TXA use outcomes in military casualties documented an increased rate of venous thromboembolism in patients receiving TXA. Estimates of TXA effects on mortality suggested that an adequately powered study would likely observe an effect size in line with CRASH-2 findings.
This survival benefit associated with TXA supports its use in conjunction with damage control resuscitation following combat injury. This association is most prominent in those requiring massive transfusion.\textsuperscript{14,74} In casualties at high risk of hemorrhagic shock, \textit{TXA reduces mortality IF GIVEN WITHIN THREE (3) HOURS of injury}, optimal use of TXA requires that it be given as soon as possible when indicated rather than suggesting that TXA administration any time within 3 hours after injury is acceptable.\textsuperscript{75,76} TXA given empirically greater than 3 hours post-injury increases the risk of mortality. For eligible casualties, one gram of TXA should be administered IV or IO, followed by another gram over 8 hours. (See next section \textit{Recognition of Patients Requiring DCR} to determine eligible casualties.) The first gram is ideally administered in 100 ml of normal saline over 10 minutes, but faster administration in more concentrated form can be considered. Administration of undiluted TXA by slow IV push (given over 10 minutes) is acceptable if supplies or tactical situation prevents 100mL IV infusion.\textsuperscript{77} It should be noted that rapid infusion of TXA has been infrequently associated with transient hypotension. Although Lactated Ringer’s (LR) solution is compatible with TXA, its use should be avoided in this setting since the mixing of calcium-containing LR with blood products in chaotic resuscitation settings may cause clotting of blood products and thromboembolic phenomena. Normal saline and PlasmaLyte A are the only crystalloid solutions compatible with blood products.

Hypocalcemia is a problem in most actively bleeding trauma patients on presentation, and administration of even one unit of citrated blood product can further lower ionized calcium to levels approaching critical values (<0.9mmol/l). One gram of calcium (30 ml of 10% calcium gluconate or 10 ml of 10% calcium chloride) IV/IO should be given to patients in hemorrhagic shock during or immediately after transfusion of the first unit of blood product and with ongoing resuscitation after every 4 units of blood products. At a minimum, one 10 ml ampule of 10% CaCl$_2$, or 30 ml of 10% calcium gluconate, should be administered after no more than 4 units of blood product have been infused to avoid citrate toxicity. Ideally, ionized calcium should be monitored and calcium should be given for ionized calcium less than 1.2mmol/L. This should be done at the first level of care capable of monitoring these patients, typically a Role 2 equivalent or above. Appropriate calcium solutions should otherwise be administered per protocol for signs and symptoms of hypocalcemia (e.g., prolonged QTc, ventricular arrhythmias, decreased cardiac output/cardiovascular collapse, coagulopathy, tetany, laryngospasm, seizures, and paresthesia). Note that hypomagnesemia is also common in trauma patients and is worsened by citrate-containing blood products. Hypomagnesemia may contribute to increased cardiac irritability and risk of fatal arrhythmias. Consideration should be given to replacing magnesium in the setting of severe hypocalcemia and massive transfusion.\textsuperscript{4,78-80}

The use of rFVIIa is no longer recommended in most trauma patients since it has not been shown to reduce mortality and may increase risk of adverse events.\textsuperscript{81-85}

\section*{RECOGNITION OF PATIENTS REQUIRING DCR}

Patients receiving uncrossmatched Type O blood in the Emergency Department (ED) or resuscitation area and later receiving cumulative transfusions of 10 or more RBC units in the initial 24 hours post-injury (MT) are widely recognized as being at increased risk of morbidity and mortality due to exsanguination. Ideally, these patients should be rapidly identified and hemostasis established at the earliest level of care possible in order to prevent or mitigate shock and coagulopathy. Due to diagnostic challenges, particularly in the case of truncal hemorrhage, anticipating the transfusion needs of these
patients requires experience and the coordination of extensive resources, including development of MT protocols.

Robust pre-hospital data are lacking, but a number of factors predict the need for MT support in trauma. In a patient with serious injuries, the presence of 3 of the 4 features below indicates a 70% predicted risk of MT and 85% risk if all 4 are present:

- Systolic blood pressure < 100 mm Hg
- Heart rate > 100 bpm
- Hematocrit < 32%
- pH < 7.25

Other risk factors associated with MT or at least need for aggressive resuscitation:

- Injury pattern (above-the-knee traumatic leg amputation especially if pelvic injury is present, multi-amputation, clinically obvious penetrating injury to chest or abdomen)
- >2 regions positive on FAST scan
- Lactate concentration on admission >2.5
- Admission INR ≥ 1.5
- BD > 6 mEq/L

Recognition of clinical patterns associated with the need for MT is essential for effective triage. These include: uncontrolled truncal or junctional bleeding, uncontrolled major bleeding secondary to large soft tissue injuries, proximal, bilateral, or multiple amputations, a mangled extremity, clinical signs of coagulopathy (e.g., paucity of clots or petechial bleeding), or severe hypothermia. It is critical to communicate with the blood bank at the medical treatment facility when a potential MT patient has been identified. Blood banks within theater have developed procedures for providing blood products in the appropriate proportion to support resuscitative efforts. Upon arrival to the ED, laboratory evaluation such as viscoelastic testing (TEG or ROTEM) may also facilitate early identification of patients who will require MT, although this technology is not widely available in the deployed setting, particularly at Role 2 facilities. It should be noted that many point-of-care coagulation tests that measure Prothrombin Time/International Normalized Ratio (PT/INR) have linear ranges only between INR 2.0-3.0 and are unreliable in clinical conditions characterized by loss of fibrinogen. These devices should not be relied upon to evaluate the coagulation function in trauma patients.

---

**POINT OF INJURY, EN-ROUTE, AND REMOTE DCR**

For detailed recommendations on prolonged field care (PFC) damage control resuscitation, see the *JTS Damage Control Resuscitation for PFC CPG*, 01 Oct 2018. [https://jts.amedd.army.mil/index.cfm/PI_CPGs/cpgs](https://jts.amedd.army.mil/index.cfm/PI_CPGs/cpgs)

**OPTIMIZATION OF FLUIDS**

Volume resuscitation, particularly crystalloid and colloid, should be used sparingly in the pre-hospital setting, given the potential for harm and the limited resources; blood products are preferred for hemorrhagic shock resuscitation. WB (Group O low titer preferred) or blood components given ideally at a 1:1:1 (plasma, platelets, RBC) ratio should be transfused when shock is present or expected.
Blood products should ideally be warmed with approved in-line blood heaters with the goal of transfusing products warmed to 37°C.

Casualties at low risk of developing shock should NOT receive IV fluids or adjunctive medications.

Hypertonic Saline does NOT improve mortality in hemorrhagic shock and should only be used for patients with TBI and evidence/suspicion of raised Intracranial Pressure (ICP).\(^{96,97}\) Vasopressors are NOT recommended for the treatment of hemorrhagic shock.

A key element of fluid optimization is careful documentation of all fluids, interventions, and medications given in the pre-hospital phase.

**ADJUNCTIVE THERAPIES IN PFC**

**Compressive/hemostatic dressings and devices**

Prevent further hemorrhage with direct pressure, topical hemostatic dressings, and/or tourniquets, if possible, to minimize the risk of shock. REBOA can be highly effective if rapidly implemented by skilled and designated teams.

**Prevention of acidosis and hypothermia**

Metabolic acidosis resulting from acute trauma is a consequence of inadequate tissue perfusion leading to lactic acid production and is best addressed with resuscitation with WB or equal ratio components. Crystalloid resuscitation will contribute to the acidosis and should be avoided. Hypothermia is multifactorial and strategies should address as many causes as are identified, including cold exposure, cold resuscitation fluids, significant blood loss, and shock. Hypoperfusion contributes to development of hypothermia due to decreased heat production. Prior to arrival at the military treatment facility, heated fluids, fluid blankets, and ventilators may not be available, but wounds should be covered, “space blankets” (e.g., HPMK) used to cover the casualty, and shock avoided or treated. See [*JTS Hypothermia Prevention CPG*](#) for additional information.\(^ {98}\) In patients with isolated extremity injuries treated with tourniquets, the extremity distal to the tourniquet should be left exposed and cooled relative to the patient’s core in order to increase the likelihood of preserving the ischemic limb’s viability.\(^ {99}\)

**Expeditious delivery to definitive surgical control**

Casualties may require care as described and emergency procedures for life-threatening conditions in the pre-hospital setting; however, these should be balanced against the need to expeditiously deliver the patient to definitive care. DCS at Role 2 forward surgical units should focus only on control of hemorrhage and prevention of ongoing contamination. Only absolutely necessary procedures should be performed. In general, every effort should be made to deliver the critically injured casualty to the highest available level of care as rapidly as possible.

**DCR AT MEDICAL TREATMENT FACILITY**

Although principles remain the same, DCR in medical facilities differs in that there are more resources available, including access to operative surgical control. Also, some therapies such as TXA may have already been given in the pre-hospital phase. Resuscitation to physiologic endpoints such as lactate and base deficit should be considered since tissue hypoxia and oxygen debt are known drivers of
coagulopathy. Reversal of tissue hypoxia should thus be a central tenet of hospital-based resuscitation. Specifically:

**OPTIMIZATION OF FLUIDS**

Volume resuscitation with crystalloids should NOT be first-line of care in MTFs due to the potential for harm. Crystalloid fluids should be reserved for specific clinical uses, such as carrier fluid for intravenous medication or other non-resuscitative uses. The order of priority for fluid administration should be:

- Fully TTD tested (performed in FDA registered testing facility/FDA approved) Whole Blood;
- Blood components at a 1:1:1:1 ratio (plasma:platelets:RBC:CRYO); Note that apheresis platelets may be collected in theater and therefore are not FDA approved and fully tested prior to transfusion.
- Whole blood from a recently tested donor *(NOTE: this option is only acceptable in the hospital for emergency indications when full component therapy is not available)*;
- RBCs plus plasma=1:1 ratio;
- Plasma with or without RBCs; and
- RBCs alone.

**BLOOD PRODUCT TRANSFUSION**

Cryoprecipitate is available in hospital settings and should be added to the component mix to create a 1:1:1:1 ratio of products in order to adequately supply fibrinogen and other clotting factors (Factors VIII, XIII, and vWF).

When operationally necessary due to component shortages, WB from walking blood banks can be life-saving. For additional information, refer to the *JTS Whole Blood Transfusion CPG*.41

Continual reassessment of the casualty status is needed during and between transfusions. As the patient stabilizes, component ratios should be replaced by ‘goal-directed’ therapy guided by laboratory evaluation, including CBC, blood gases, calcium levels, PT/INR, Activated Partial Thromboplastin Time (aPTT), and viscoelastic testing (ROTEM® or TEG) if available.

**ADJUNCTIVE THERAPIES AT MEDICAL TREATMENT FACILITIES**

**Hypotensive resuscitation**

As in the pre-hospital period, resuscitation of casualties without CNS injury prior to definitive surgical control should maintain a lower target SBP (100 mmHg, range 90-110mmHg) to reduce hemorrhage by minimizing intravascular hydrostatic pressure. Hypotensive resuscitation should not be utilized for patients with isolated CNS injury because of associated adverse outcomes in this population (goal SBP >110mmHg). For additional information, see the *JTS Neurosurgery and Severe Head Injury CPG*.97

**Compressive/hemostatic dressings and devices**

Until definitive surgical control is established, prevent further hemorrhage with direct pressure, topical or truncal hemostatic dressings, and/or tourniquets or REBOA to avoid the development of shock. In extremis, procedures such as resuscitative thoracotomy are indicated. Use of these devices should occur
as rapidly as hemorrhage is identified and should not unnecessarily delay transport to the operating room.

**Prevention or correction of hyperfibrinolysis**

TXA should be given to casualties at risk of hemorrhagic shock who have not already received a dose during the pre-hospital phase. THE CASUALTY SHOULD ONLY RECEIVE INITIAL TXA IF ADMINISTERED WITHIN THREE (3) HOURS OF INJURY. When given > 3 hours post-injury, TXA increases the risk of mortality. The mortality data were not analyzed in patients with hyperfibrinolysis documented by viscoelastic testing (ROTEM® or TEG). However, documented hyperfibrinolysis in the setting of ongoing hemorrhage should be treated according to clinical judgment. For eligible casualties (see section above titled Recognition of Patients Requiring DCR), one gram of TXA should be administered IV or IO, followed by another gram over 8 hours. The first gram is ideally administered in 100 ml of normal saline over 10 minutes, but faster administration in more concentrated form can be considered. It should be noted that rapid infusion of TXA has been infrequently associated with transient hypotension.

**Prevention of acidosis and hypothermia**

Hypothermia is multifactorial and strategies should address as many causes as are identified, including cold exposure, cold resuscitation fluids, significant blood loss, and shock. Hypothermia occurs even when ambient temperatures are elevated and medical personnel are uncomfortably warm, due to blood loss and hypoperfusion. Treatment should include urgent, active re-warming with all available means including heated fluids, heated blankets, ventilators, warm environments, and rapid surgical care to minimize blood and heat loss.

**Expeditious delivery to definitive surgical control**

As with casualties in the pre-hospital setting, pre-surgical care should be balanced against the need to expeditiously deliver the patient to the operating room.

**CONCLUSION**

The DCR approach to the initial management of a critically injured casualty requires a significant expenditure of resources and the coordination of a diverse group of health care providers. This is frequently performed in a clinical scenario of multiple casualties and limited resources. It is incumbent upon the clinical leaders at each level of care to be fully versed on available resources and to employ them judiciously and appropriately. Patients requiring MT should be resuscitated using DCR principles and should undergo early DCS.

**PERFORMANCE IMPROVEMENT (PI) MONITORING**

**POPULATION OF INTEREST**

1. All patients who receive blood product transfusion within 3 hours of injury

2. All patients with severe traumatic injury (ISS ≥16 and ≥ 2 body regions injured with AIS severity ≥ 2 AND SBP < 100 OR HR > 100 OR hematocrit < 32% OR pH <7.25 within 3 hours of injury)
3. Massive transfusion includes all patients who received 10 or more units of RBC + WB within first 24 hours.

**INTENT (EXPECTED OUTCOMES)**

1. All patients in the population of interest receive TXA within 3 hours after injury.
2. All patients in the population of interest who receive 1 or more units of blood product also receive calcium.
3. All MT patients receive transfusion of plasma:RBC in a ratio between 0.5:1 to 1:1.5.
4. All MT patients receive platelet or WB transfusion.
5. All MT patients receive cryoprecipitate or WB.
6. For the population of interest, the first resuscitation fluid given after injury is a blood product, ideally cold-stored LTOWB.

**PERFORMANCE/ADHERENCE METRICS**

1. Number and percentage of patients in the population of interest who receive TXA within 3 hours after injury (or documented ROTEM indicating no fibrinolysis).
2. Number and percentage of patients in the population of interest receiving 1 or more units of blood product who also receive calcium.
3. Number and percentage of MT patients who receive plasma:RBC in a ratio between 0.5:1 to 1:1.5. (calculate ratio for first 24 hours).
4. Number and percentage of MT patients who receive platelet or WB transfusion.
5. Number and percentage of MT patients who receive cryoprecipitate or WB.
6. Number and percentage of patients in population of interest who received a blood product as the first resuscitation fluid.
7. Number and percentage of patients in population of interest who received cold-stored LTOWB as the first resuscitation fluid.

**DATA SOURCES**

- Patient Record
- Department of Defense Trauma Registry (DoDTR)
- Theater Medical Data Store
SYSTEM REPORTING & FREQUENCY

The above constitutes the minimum criteria for PI monitoring of this CPG. System reporting will be performed annually; additional PI monitoring and system reporting may be performed as needed.

The system review and data analysis will be performed by the JTS Chief, JTS Program Manager, and the JTS PI Branch.

RESPONSIBILITIES

It is the trauma team leader’s responsibility to ensure familiarity, appropriate compliance and PI monitoring at the local level with this CPG.

REFERENCES


APPENDIX A: EXAMPLE OF A MASSIVE TRANSFUSION PROCEDURE AT USCENTCOM LEVEL III FACILITY

CONSIDERATIONS FOR USE WITH MASSIVE TRANSFUSION (MT)

- A flexible procedure for use in the Emergency Department (ED), Operating Room (OR) and Intensive Care Unit (ICU) which can be initiated or ceased by the site-specific provider as dictated by the patient’s needs when in that specific venue. It consists of batches as defined below, which vary in composition, but are directed toward approximating a 1:1:1:1 ratio of FFP, platelets, RBC, and cryoprecipitate (CRYO). Note: one unit of apheresis platelets is approximately the equivalent of 6 units random donor platelets, therefore 1u apheresis platelets should be given for every 6 units of RBC to approximate 1:1:1 resuscitation. Crystalloid infusion should be minimized and limited to use as carrier fluid. Hextend® should not be used.

- Note that the MT protocol described below is designed for use with blood components and is designed to provide the functionality of WB. If using WB for MT, the considerations that can be applied from the protocol below include early use of TXA and calcium. Also, if using primarily CWB that has been stored for more than 2 weeks, consider supplementing with additional platelets, either from FWB (consider a ratio of 3:1 of CWB: FWB as available) or from apheresis platelets (consider adding 1 unit of platelets after every 6-10 CWB units if clinically indicated).

Initiate MT procedure if patient has received 4u RBC/4u FFP emergency release blood products.

- Pack One: 6u RBC, 6u FFP, 1u apheresis platelets, 1-2 5-unit bags of cryo. Give TXA empirically if within 3 hours of injury: Infuse 1 gram of tranexamic acid in 100 ml of 0.9% NS over 10 minutes intravenously in a separate IV line from any containing blood and blood products. (A more concentrated or rapid injection can be considered but rapid TXA infusion has been infrequently reported to cause transient hypotension.) Infuse a second 1-gram dose of TXA intravenously over 8 hours infused with 0.9% NS carrier. Give one gram calcium during or immediately after first blood product administered and another gram after every four units of blood product.

- Pack Two: 6u RBC, 6u FFP, 1u apheresis platelets, 1-2 5-unit bags of cryo. Continue to monitor ionized calcium or give 1gm calcium after every 4 blood products.

- Pack Three and beyond: identical to Pack Two

Definitions

Emergency Release: Uncrossmatched 4u RBC (generally O+ but may be O- for females under the age of 50 if available) and 4u AB or A plasma (NOTE: A plasma is not “universal” but risk of hemolysis in B or AB patients is very low and its use in massive transfusion patients when supplies of AB FFP are limited or absent may improve survival and help preserve resources. A plasma is commonly used as emergency release plasma throughout the United States.)
APPENDIX B: PEDIATRIC CONSIDERATIONS

There are no prospective studies of transfusion resuscitation in pediatric trauma. Most major children’s centers extrapolate from adult literature and are using similar damage control resuscitation strategies in major hemorrhage. There are currently no data determining which patients may benefit from these strategies. See Appendix A for a suggested MT Protocol.

For children under a weight of 30 Kilograms (KG), transfusions of RBC units, FFP, or apheresis platelets should be given in “units” of 10-15 ml/kg. One unit of cryoprecipitate is typically administered for every 10 kg of body weight. Blood volume in children can be estimated at between 60-80ml/kg. Bear in mind that a “trauma pack” containing 6 U RBCs + 6 U FFP + 1 U apheresis platelets will deliver between 3000-4000ml of intravascular volume. A child of 30kg may have a TOTAL blood volume of 1800-2400ml. Over-resuscitation contributes to morbidity and mortality. It may be more convenient and safe to resuscitate children with WB since this product delivers full oxygen delivery and hemostatic functionality and may support more accurate volume dosing. For example, a typical unit of whole blood contains about 500-600ml (depending on bag type and volume: 450 or 500ml blood volume plus anticoagulant). For a severely injured, shocked child, a quarter to a half of a WB unit may provide adequate initial resuscitation, which can then be further titrated.

Pediatric approved Intraosseous (IO) devices can be used for transfusion if required. Note that sternal IOs designed for adults may pierce a child’s sternum and deliver fluids or blood products into the mediastinum.

A MT in pediatrics has been defined as ≥40ml/kg of blood products in 24 hours. The circulating blood volume in children is approximately 60-80 ml/kg. Children are at high risk of developing hypocalcemia, hypomagnesemia, metabolic acidosis, hypoglycemia, hypothermia and hyperkalemia during MTs. Therefore, frequent monitoring and correction of acid/base status, electrolytes, and core temperature is essential during the resuscitation of pediatric casualties. An approved blood warmer and other transdermal temperature management system devices are recommended for the prevention and treatment of hypothermia.

Although there are limited retrospective data demonstrating the benefit of TXA in pediatric trauma, there are studies of TXA use in pediatric cardiac, orthopedic and cranial surgeries showing overall safety and decreased transfusion requirements. There is no prospectively validated dosing available for pediatric trauma but loading doses of 10-100 mg/kg IV followed by 5-10 mg/kg/hour infusion doses are commonly used in elective surgery. The UK Royal College of Pediatrics and Child Health has recommended a loading dose of 15mg/kg (up to 1 gm) followed by 2mg/kg/hr over 8 hours (or up to 1gm over 8 hours). This regimen reflects standard adult dosing in trauma.

Viscoelastic clot testing (e.g., TEG or ROTEM®) can be utilized to direct transfusion requirements as in adults utilizing the same thresholds discussed in this CPG. Viscoelastic testing should not be used to withhold TXA during initial resuscitation of bleeding trauma patients.

Prolonged CPR > 20-30 min is generally futile in children who have cardiac arrest with trauma related injuries. Children with traumatic injuries with in-hospital cardiac arrest have a very high mortality after 20-30 min of cardiac arrest.
References for Pediatric Considerations:


APPENDIX C: ADDITIONAL INFORMATION REGARDING OFF-LABEL USES IN CPGS

PURPOSE

The purpose of this Appendix is to ensure an understanding of DoD policy and practice regarding inclusion in CPGs of “off-label” uses of U.S. Food and Drug Administration (FDA)–approved products. This applies to off-label uses with patients who are armed forces members.

BACKGROUND

Unapproved (i.e. “off-label”) uses of FDA-approved products are extremely common in American medicine and are usually not subject to any special regulations. However, under Federal law, in some circumstances, unapproved uses of approved drugs are subject to FDA regulations governing “investigational new drugs.” These circumstances include such uses as part of clinical trials, and in the military context, command-required, unapproved uses. Some command-requested, unapproved uses may also be subject to special regulations.

ADDITIONAL INFORMATION REGARDING OFF-LABEL USES IN CPGS

The inclusion in CPGs of off-label uses is not a clinical trial, nor is it a command request or requirement. Further, it does not imply that the Military Health System requires that use by DoD health care practitioners or considers it to be the “standard practice.” Rather, the inclusion in CPGs of off-label uses is to inform the clinical judgment of the responsible health care practitioner by providing information regarding potential risks and benefits of treatment alternatives. The decision is for the clinical judgment of the responsible health care practitioner within the practitioner-patient relationship.

ADDITIONAL PROCEDURES

Balanced Discussion

Consistent with this purpose, CPG discussions of off-label uses specifically state that they are uses not approved by the FDA. Further, such discussions are balanced in the presentation of appropriate clinical study data, including any such data that suggest caution in the use of the product and specifically including any FDA-issued warnings.

Quality Assurance Monitoring

With respect to such off-label uses, DoD procedure is to maintain a regular system of quality assurance monitoring of outcomes and known potential adverse events. For this reason, the importance of accurate clinical records is underscored.

Information to Patients

Good clinical practice includes the provision of appropriate information to patients. Each CPG discussing an unusual off-label use will address the issue of information to patients. When practicable, consideration will be given to including in an appendix an appropriate information sheet for distribution to patients, whether before or after use of the product. Information to patients should address in plain language: a) that the use is not approved by the FDA; b) the reasons why a DoD health care practitioner would decide to use the product for this purpose; and c) the potential risks associated with such use.